This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (9)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Alzheimer Disease  • Neuropathology  • Alert me on articles by topic

Arch Neurol. 2001;58:349-350.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

DEMENTIA DUE TO Alzheimer disease (AD) is a diagnosis based on impaired performance on mental status assessments and evidence of impaired function in daily affairs. Neurologists, geriatricians, and psychiatrists who see many cases of dementia can usually make the diagnosis with confidence. However, among a large group of other physicians, the diagnosis of AD is perceived as uncertain. In order to enhance precision of the diagnosis, biomarkers, such as the combined use of the cerebrospinal fluid (CSF) ß-amyloid (Aß) peptide and tau protein, have recently been the subject of several investigations.^{1, 2, 3}

In this issue of the ARCHIVES, Andreasen and coworkers⁴ have made a substantial contribution to the field by carrying out a population-based analysis of CSF Aß and tau protein in a group of 240 patients with dementia in Piteå, a community in northern Sweden. While Andreasen and colleagues did not have the opportunity to study nondemented individuals in their . . . [Full Text of this Article]

RELATED ARTICLE

Evaluation of CSF-tau and CSF-Aß42 as Diagnostic Markers for Alzheimer Disease in Clinical Practice
Niels Andreasen, Lennart Minthon, Pia Davidsson, Eugeen Vanmechelen, Hugo Vanderstichele, Bengt Winblad, and Kaj Blennow
Arch Neurol. 2001;58(3):373-379.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Haptoglobin-{alpha} Subunit As Potential Serum Biomarker in Ovarian Cancer: Identification and Characterization Using Proteomic Profiling and Mass Spectrometry
Ye et al.
Clin. Cancer Res. 2003;9:2904-2911.
ABSTRACT | FULL TEXT  

Alzheimer Disease: Current Concepts and Emerging Diagnostic and Therapeutic Strategies
Clark and Karlawish
ANN INTERN MED 2003;138:400-410.
ABSTRACT | FULL TEXT  

CSF A{beta} 42 levels correlate with amyloid-neuropathology in a population-based autopsy study
Strozyk et al.
Neurology 2003;60:652-656.
ABSTRACT | FULL TEXT  

Cerebrospinal Fluid Tau and {beta}-Amyloid 42 Proteins Identify Alzheimer Disease in Subjects With Mild Cognitive Impairment
Riemenschneider et al.
Arch Neurol 2002;59:1729-1734.
ABSTRACT | FULL TEXT